THERAPEUTIC SEGMENT:
Cardiology

INDICATIONS:
Bilinta is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).

Bilinta has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction, or stroke compared to clopidogrel.

In patients treated with PCI, it also reduces the rate of stent thrombosis.

BRIEF DESCRIPTION:
Bilinta is antiplatelet medication which decrease the risk of heart attack, death, and stroke in people with acute coronary syndrome (ACS), prior heart attacks, or stents. It also lowers the risk of first heart attack or stroke in high-risk coronary artery disease (CAD) patients and helps prevent strokes in those with acute ischemic stroke or mini-strokes.

DOSAGE FORM:
Tablets
90mg

Disclaimer: For use under medical prescription only